Oruka Therapeutics (FRA:HQ1) Accounts Payable : €3.31 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Accounts Payable?

Oruka Therapeutics's Accounts Payable for the quarter that ended in Dec. 2024 was €3.31 Mil.

Oruka Therapeutics's quarterly Accounts Payable stayed the same from . 20 (€0.00 Mil) to . 20 (€0.00 Mil) but then increased from . 20 (€0.00 Mil) to Dec. 2024 (€3.31 Mil).

Oruka Therapeutics's annual Accounts Payable stayed the same from . 20 (€0.00 Mil) to . 20 (€0.00 Mil) but then increased from . 20 (€0.00 Mil) to Dec. 2024 (€3.31 Mil).

Oruka Therapeutics Accounts Payable Historical Data

The historical data trend for Oruka Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Accounts Payable Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Accounts Payable

3.31

Oruka Therapeutics Semi-Annual Data
	Dec24
Accounts Payable	3.31

Oruka Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Oruka Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

ORKA:USA

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines